A specific monoclonal antibody targeting C-36 peptide of alpha1-antitrypsin as a tool in respiratory research

S. Tumpara (Hannover, Germany), E. Korenbaum (Hannover, Germany), T. Welte (Hannover, Germany), B. Martinez Delgado (Madrid, Spain), S. Janciauskiene (Hannover, Germany)

Source: Virtual Congress 2021 – Biomarkers for the management of bronchial obstructive diseases
Session: Biomarkers for the management of bronchial obstructive diseases
Session type: E-poster
Number: 1151

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Tumpara (Hannover, Germany), E. Korenbaum (Hannover, Germany), T. Welte (Hannover, Germany), B. Martinez Delgado (Madrid, Spain), S. Janciauskiene (Hannover, Germany). A specific monoclonal antibody targeting C-36 peptide of alpha1-antitrypsin as a tool in respiratory research. 1151

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Specific monoclonal antibody to detect the C-terminal peptide of alpha1-antitrypsin: clinical importance
Source: International Congress 2019 – Chronic cough, a1-antitrypsin deficiency and other conditions
Year: 2019

The type II and clara cell specific monoclonal antibody (MMC4) recognises aminopeptidase N
Source: Eur Respir J 2004; 24: Suppl. 48, 719s
Year: 2004

Effects of anti-M1 prime monoclonal antibody, MEMP1972A following allergen challenge in patients with mild asthma
Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD
Year: 2012

Reversing the suppression of T-cells: the role of monoclonal antibodies
Source: International Congress 2015 – Stop immune tolerance in lung cancer!
Year: 2015



A novel anti-IgE immunotherapeutic, RP01, induces anti-IgE antibodies in human subjects; data from a phase I study
Source: Eur Respir J 2007; 30: Suppl. 51, 622s
Year: 2007

Phase 1 study of a novel, prolonged-action anti-IL-5 monoclonal antibody in asthma
Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence
Year: 2021



An anti-human ICAM-1 antibody inhibits human rhinovirus infection in the mouse model of human major group rhinovirus infection
Source: Annual Congress 2011 - Insight into mechanisms of respiratory infections
Year: 2011

Is Fezakinumab, an anti-IL22 antibody, a putative novel therapy for a subset of severe asthma?
Source: International Congress 2019 – Novel molecular pathways in lung cancer and COPD
Year: 2019



Rapid reversal of radiation-induced murine pneumonitis by treatment with the anti-CTGF monoclonal antibody FG-3019
Source: Annual Congress 2011 - Experimental models and research in diffuse parenchymal lung diseases
Year: 2011

Subcutaneuous injection of monoclonal antibody anti-DEC205 conjugated with ovalbumin atenuates allergic lung inflammation of animals previously sensitized to allergen
Source: Annual Congress 2012 - Mechanisms and modulation of allergic inflammation in the lung
Year: 2012

Endothelial eNAMPT amplifies pre-clinical acute lung injury: efficacy of an eNAMPT-neutralising monoclonal antibody
Source: Eur Respir J, 57 (5) 2002536; 10.1183/13993003.02536-2020
Year: 2021



Monitoring of monoclonal antibody therapy with a new recovery ELISA assay technique (R-ELISA®)
Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management
Year: 2010

Novel inhaled delivery of anti-IL-13 mAb (Fab fragment): preclinical efficacy in allergic asthma
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017

A patient-derived lung-on-chip model to evaluate on-target/off-tumour toxicity of the therapeutic FOLR1-targeting T-Cell Bispecific antibody
Source: Virtual Congress 2021 – In vitro modelling of lung disease: reach out to the next dimension
Year: 2021


PP129 – Safety evaluation of cancer immunotherapy in a lung-on-chip model: the therapeutic FOLR1 targeting T Cell Bispecific antibody
Source: ERS Lung Science Conference 2021
Year: 2021

MEMP1972A, an anti-M1 prime monoclonal antibody, reduces serum IgE in healthy and allergic rhinitis subjects
Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD
Year: 2012

Anti-immunoglobulin E antibodies may improve remodeling in a mouse model of asthma
Source: Annual Congress 2011 - Asthma: control and treatment
Year: 2011

Preclinical development of an IL-13 neutralising antibody, CAT-354, for the treatment of human asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 367s
Year: 2005

Efficacy and safety of anti-PD-L1 antibody in NSCLC patients who previously treated with anti PD-1 antibodies
Source: International Congress 2019 – Treatment of lung cancer
Year: 2019


The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma
Source: Eur Respir J 2001; 18: 45-52
Year: 2001